I expect this would be a pretty small market for CHM initially.
12,000 cases in the USA annually. How many of those would make it to 3rd line therapy (our initial target indication)? Will insurers pay $0.5-1m for a therapy which extends life by 10 months? Will patients be willing to pay that?
If CHM can progress to SoC, and can show some great results when used earlier in the course of disease, then it would be more commercially attractive. But that could take quite some time.
Ann: New data for Phase 1A CLTX CAR T brain cancer clinical trial, page-66
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $6.106K | 1.526M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 10128436 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14333527 | 23 |
View Market Depth
| Last trade - 09.59am 25/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |